Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yestar Healthcare Holdings Company Limited (2393.HK)
Pudong, BJ, CN
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents. The company also engages in the management of supply chain and service of freight transportation equipment, as well as development of biotechnology. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People’s Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.85% | +0.00% | -25.27% | -40.35% | -45.16% | -32.67% | -23.60% | -76.14% | -94.09% | -97.94% | -82.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%-38.2% Q4'25: -52.3% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-108.1% Q4'25: -652.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+16.2% Q4'25: +11.8% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+0.8% Q4'25: -3.5% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+3.4% Q4'25: -25.1% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×5.61× ★ Q4'25: -4.59× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.53B
est: 1.24B (+23.3%)
|
2.45B
est: 2.92B (-15.9%)
|
3.02B
est: 3.58B (-15.6%)
|
3.93B
est: 4.37B (-10.1%)
|
4.45B
est: 5.26B (-15.5%)
|
4.90B
est: 6.07B (-19.2%)
|
4.11B
est: 5.37B (-23.5%)
|
4.93B
est: 5.98B (-17.6%)
|
2.80B
est: 4.86B (-42.3%)
|
2.91B
est: 4.85B (-40.0%)
|
2.41B
est: 4.62B (-47.8%)
|
| EBITDA |
164.61M
est: 62.85M (+161.9%)
|
349.60M
est: 209.45M (+66.9%)
|
514.76M
est: 331.69M (+55.2%)
|
783.62M
est: 351.65M (+122.8%)
|
802.43M
est: 434.25M (+84.8%)
|
860.91M
est: 441.72M (+94.9%)
|
305.49M
est: 399.31M (-23.5%)
|
315.89M
est: 449.18M (-29.7%)
|
19.13M
est: 520.57M (-96.3%)
|
376.81M
est: 597.88M (-37.0%)
|
-51.93M
est: 188.28M (-127.6%)
|
| EBIT |
147.79M
est: 5.30M (+2,689.4%)
|
292.17M
est: 204.90M (+42.6%)
|
422.88M
est: 358.10M (+18.1%)
|
645.45M
est: 446.47M (+44.6%)
|
650.31M
est: 647.95M (+0.4%)
|
611.20M
est: 664.94M (-8.1%)
|
158.14M
est: 515.29M (-69.3%)
|
184.37M
est: 579.64M (-68.2%)
|
-211.64M
est: 671.76M (-131.5%)
|
205.75M
est: 771.53M (-73.3%)
|
-119.86M
est: -8.28M (-1,346.7%)
|
| Net Income |
100.90M
est: 100.03M (+0.9%)
|
162.76M
est: 135.33M (+20.3%)
|
201.03M
est: 190.69M (+5.4%)
|
249.97M
est: 201.08M (+24.3%)
|
251.75M
est: 244.91M (+2.8%)
|
202.67M
est: 257.43M (-21.3%)
|
-590.49M
est: 176.05M (-435.4%)
|
3.33M
est: 198.03M (-98.3%)
|
-992.23M
est: 229.51M (-532.3%)
|
-13.89M
est: 263.59M (-105.3%)
|
921.61M
est: -28.58M (+3,324.5%)
|
| SGA |
115.68M
est: 172.90M (-33.1%)
|
225.24M
est: 155.15M (+45.2%)
|
343.46M
est: 263.89M (+30.2%)
|
460.37M
est: 343.53M (+34.0%)
|
548.52M
est: 451.05M (+21.6%)
|
654.11M
est: 560.90M (+16.6%)
|
623.46M
est: 568.18M (+9.7%)
|
657.01M
est: 639.14M (+2.8%)
|
364.90M
est: 740.72M (-50.7%)
|
380.58M
est: 850.72M (-55.3%)
|
362.41M
est: 650.15M (-44.3%)
|
| EPS |
0.05
est: 0.04 (+25.9%)
|
0.08
est: 0.08 (+5.6%)
|
0.09
est: 0.12 (-22.9%)
|
0.11
est: 0.11 (+2.9%)
|
0.12
est: 0.13 (-10.2%)
|
0.08
est: 0.13 (-36.0%)
|
-0.25
est: -0.01 (-3,351.5%)
|
0.00
est: 0.08 (-98.2%)
|
-0.20
est: -0.11 (-76.5%)
|
0.00
est: -0.05 (+92.5%)
|
0.40
est: -0.01 (+3,363.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changxiang Liao | Executive Director & GM for Guangxi Operation | 2M | female |
| Jinrong Qiao | Chief Financial Officer & Executive Director | 829.0K | male |
| Chunlai Wang | Chief Executive Officer & Executive Director | 650.1K | male |
| Tsz Hin Ngai | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2393.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
